1 Low dose prime and delayed boost can improve COVID-19 vaccine efficacies by

2	increasing	R	cell	SP	lection	string	enev	in	germinal	centres
_	mer casing	•	CCII	50		String	CHCy	111	ger iiiiiiai	CCIILICS

3

21

22

Amar K. Garg^{1,#}, Soumya Mittal¹, Pranesh Padmanabhan², Rajat Desikan^{1,‡}, Narendra M. Dixit^{1,3,*} 5 ¹Department of Chemical Engineering, Indian Institute of Science, Bangalore, India 560012 ²Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, Brisbane, Australia 4072 ³Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, India 560012 *Current Address: Helmholtz Centre for Infection Research, Braunschweig, Germany [‡]Current Address: Certara QSP, Certara UK Limited, Sheffield, UK 12 *Correspondence: Narendra M. Dixit 14 Email: narendra@iisc.ac.in 15 Address: Department of Chemical Engineering, Indian Institute of Science, Bangalore, 560012, Karnataka, 16 India 17 18 19 20

23 ABSTRACT

The efficacy of COVID-19 vaccines appears to depend in complex ways on the vaccine dosage 24 and the interval between the prime and boost doses. Unexpectedly, lower dose prime and longer 25 prime-boost intervals have yielded higher efficacies in clinical trials. To elucidate the origins 26 of these effects, we developed a stochastic simulation model of the germinal centre (GC) 27 reaction and predicted the antibody responses elicited by different vaccination protocols. The 28 simulations predicted that a lower dose prime could increase the selection stringency in GCs 29 due to reduced antigen availability, resulting in the selection of GCB cells with higher affinities 30 for the target antigen. The boost could relax this selection stringency and allow the expansion 31 of the higher affinity GC B cells selected, improving the overall response. With a longer dosing 32 interval, the decay in the antigen with time following the prime could further increase the 33 selection stringency, amplifying this effect. The effect remained in our simulations even when 34 new GCs following the boost had to be seeded by memory B cells formed following the prime. 35 These predictions offer a plausible explanation of the observed paradoxical effects of dosage 36 and dosing interval on vaccine efficacy. Tuning the selection stringency in the GCs using 37 prime-boost dosages and dosing intervals as handles may help improve vaccine efficacies. 38

INTRODUCTION

The COVID-19 pandemic continues to rage and warrants intensifying the ongoing global 40 vaccination programs (1, 2). With limited vaccine supplies, it becomes critical to identify 41 dosing protocols that would maximize vaccine efficacy (3, 4). With the Oxford-AstraZeneca 42 vaccine, where dosing protocols were adjusted during the trials, data has become available of 43 the effects of different dosages used for the prime and boost doses and of different intervals 44 separating them on vaccine efficacy (5-8). A recent study has also examined the effects of increasing the interval beyond those in the trials (9). Intriguingly, the efficacy in preventing 46 symptomatic infection was 63.1% when a standard dose (containing 5×10^{10} virus particles) was 47 used for both prime and boost, whereas the efficacy was substantially higher, 80.7%, when a 48 low dose prime (containing 2.2×10^{10} virus particles) followed by the standard dose boost was 49 administered (5). Furthermore, the efficacy increased with the interval between the prime and 50 boost, from 55.1% at <6 weeks to 81.3% at \geq 12 weeks, when standard doses were used for 51 both (5). Inspired by these observations, studies are examining the effects of lower dosages and 52 increased dosing intervals with other vaccines too, specifically the Pfizer-BioNTech (10-12) 53 and Moderna (13) vaccines. An understanding of these effects would help identify optimal 54 dosing protocols and maximize the impact of the ongoing vaccination programs. The origins 55 of the effects remain to be elucidated. 56

While the role of cellular immunity is yet to be fully elucidated (14), several studies suggest that the efficacy of currently approved COVID-19 vaccines is attributable to the neutralizing antibodies they elicit (6, 11, 15-20). The higher efficacies observed above are thus argued to be due to the improved quality and quantity of the antibodies produced by the

associated dosing protocols (5, 8, 9, 11, 21). For instance, higher antibody levels were observed following the boost upon increasing the dosing interval (9, 10). In some cases, antibody-dependent cellular functions too appeared to be better with the longer intervals (21). A question that arises is how the different dosing protocols elicit antibodies of different amounts and affinities for their targets.

Antibody production following vaccination (or natural infection) occurs in germinal 66 centers (GCs) (22, 23). GCs are temporary anatomical structures assembled in lymphoid organs where B cells are locally selected based on the ability of their receptors to bind and internalize 68 antigen presented as immune complexes on follicular dendritic cell surfaces in the GCs. (GCs 69 can last anywhere from a few weeks to many months (23-25).) This process, termed affinity 70 maturation, culminates, typically in weeks, in the selection of B cells with affinities that can be 71 several orders of magnitude higher for the target antigen than those at the start of the GC reaction (26, 27). What determines the final affinities is an important question in immunology 73 and is yet to be resolved (28-30). Several studies have identified factors that influence affinity 74 maturation (26, 31-37). A key factor is antigen availability within GCs-related here to the 75 vaccine dosage and antigen half-life-elucidated first by the classic experiments of Eisen and 76 colleagues (26): B cells compete for antigen in the GCs. Their survival depends on how much 77 antigen they acquire, as we explain below. Thus, if antigen is scarce, the selection is stringent 78 and leads to the survival of those B cells that have high affinity for the target antigen. This 79 phenomenon governing the GC reaction is manifested widely, including in the effects of 80 passive immunization following HIV infection, and can be potentially exploited by tuning 81 antigen availability (34, 35, 38, 39). 82

Here, we reasoned that one way in which the effects of the different vaccination 83 protocols could arise was from the influence the protocols had on antigen availability and hence 84 selection stringency within GCs. Specifically, low dose prime is expected to result in low 85 antigen availability and may lead to the selection of higher affinity B cells. The standard dose 86 boost could then enable the expansion of these higher affinity B cells. With a larger dosing 87 interval, the decay of antigen between doses could cause an increase in selection stringency, 88 resulting in a similar effect. To test this hypothesis, we developed a detailed stochastic 89 simulation model of the GC reaction. Such simulation models have been shown to mimic the 90 GC reaction faithfully and have helped resolve confounding experimental observations and 91 predict optimal vaccination protocols (34-36, 39-44). 92

RESULTS

93

95

Stochastic simulation model of the GC reaction post COVID-19 vaccination

We present an overview of the model here (Fig. 1); details are in Methods. We 96 considered individuals who were not previously infected and were administered COVID-19 97 vaccines. We focused on the GC reaction in such individuals. The simulation, building on 98 previous protocols (35, 36, 39, 40, 42), considered and modelled events within an individual 99 GC. The GC reaction is initiated by B cells of low affinity for a target, non-mutating antigen. 100 The target could be a portion of or the entire spike protein of SARS-CoV-2. We simulated the 101 ensuing affinity maturation process using a discrete generation, Wright-Fisher-type, formalism 102 (36, 39). The GC is divided into a light zone and a dark zone (Fig. 1A). The antigen is presented 103 in the light zone and is represented as a bit-string of L amino acids. Each B cell is identified by 104

105

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

its B cell receptor (BCR), which is also represented as a bit-string of L amino acids. The affinity of a B cell for the antigen is determined by the extent of the match between the BCR and antigen sequences (39, 42), defined here using ε . ε =0 if the two sequences are completely distinct, whereas $\varepsilon = L$ if they are identical. The higher the ε , the higher is the affinity. In each generation, we let each B cell have an average of η attempts to acquire antigen. η thus serves as a surrogate of antigen availability in the GC (39). The probability with which a B cell acquires antigen in each attempt is set proportional to its affinity for the antigen (39). If a B cell fails to acquire a minimum amount of antigen, it is assumed to undergo apoptosis (31), and is eliminated. The surviving B cells then compete for help from T follicular helper (T_{fh}) cells. The probability that a B cell receives such help is set proportional to the amount of antigen it has acquired relative to that of the other B cells in the generation (39). B cells that do not succeed in receiving $T_{\rm fb}$ help are again assumed to undergo apoptosis (31). Among the surviving B cells, following previous studies (39), we let 5% exit the GC, become plasma cells, and produce antibodies; 5% exit and become memory B cells; and 90% migrate to the dark zone, where they proliferate and mutate their BCR genes and return to the light zone (39, 43). The latter B cells form the pool for the next generation of the GC reaction. The antibodies produced by plasma cells can feedback into the GC and, by displacing lower affinity antibodies in the immune complexes or by masking antigen, tend to increase the selection stringency (35, 39, 45).

Following dosing, antigen is trafficked to the lymph nodes, where its levels rise rapidly and then decline exponentially (34, 46). Accordingly, we let η rise immediately upon dosing to a pre-determined amount dependent on the vaccine dosage and then decrease with each generation based on the half-life of the administered antigen (Fig. 1B). With the boost, we

considered two scenarios (34, 47, 48): the first where the boost enhanced antigen levels in preexisting GCs, and the second where it initiated new GCs using memory B cells formed by the prime.




Figure 1. Schematic of the GC reaction model post vaccination. (A) The GC reaction. The antigen from the vaccine enters the GC complexed to antibodies and is presented in the light zone on the surfaces of follicular dendritic cells attached to FcγRIIB or CR2 receptors. GC B cells acquire antigen with a probability proportional to their affinity for the antigen. They then

130

131

132

133

receive help from T follicular helper cells with a probability dependent on the relative amount of antigen they acquired. Cells that fail to acquire antigen or receive the latter help die. Cells that succeed can exit the GC to become plasma cells and secrete antibodies, become memory B cells, or migrate to the dark zone, where they proliferate and mutate their antibody genes. The latter cells circulate back to the light zone and become subjected to the same selection process. Antibodies secreted by plasma cells can feedback into the GC and affect the selection process. (B) Schematic of the simulations. (Top) Timeline showing dose administration and corresponding antigen levels. (Bottom) GCs are formed following the prime and gradually shrink with time due to decreasing antigen levels. The prime could be low dose (LD) or standard dose (SD). The boost could restore existing GCs (mechanism I) or lead to new GCs seeded by memory B cells formed during the prime (mechanism II). The boost is typically SD.

We also examined the baseline, control scenario where the boost initiated GCs *de novo*, independently of the prime. We considered vaccination protocols with low and standard dose prime and a range of prime-boost dosing intervals. We performed multiple stochastic realizations of the simulations for each vaccination protocol and predicted the expected antibody response as an indicator of vaccine efficacy.

Antigen availability and its effect on selection stringency

To elucidate affinity maturation in the GC reaction, we first performed simulations with a constant η , set here to 7. (We considered other values of η later.) The GC initially had B cells with low affinity for the target antigen. As the GC reaction proceeded, B cells with increasing affinity were selected in our simulations, marking affinity maturation (Fig. 2A). Eventually, a stationary distribution of B cells of different affinities was achieved, dominated by B cells with the highest affinities, as observed in previous studies (39) and akin to the mutation-selection balance observed in other evolutionary simulations (49, 50). We focussed on the corresponding evolution of the average affinity of the B cells. As the GC reaction progressed, the average

affinity of the B cells increased and reached a plateau (Fig. 2B). Thus, when $\eta=7$, the average affinity of the B cells, determined by the average match-length between the antigen and BCR sequences, plateaued at ~6.7 (Fig. 2B inset). Note that L=8 in these simulations.




Figure 2. The effect of antigen availability and half-life on the GC reaction. (A) Time-evolution of populations of GC B cells of different affinity, ε , for the antigen; η =7. (B) Time-evolution of the average affinity of GC B cells for different η . *Inset*: The values at day 21 and day 80, the latter the plateau values, of the average affinity versus η . (C) Time-evolution of the affinity-weighted cumulative antibody output for different η . (D) Time-evolution of the average affinity for different antigen half-lives, τ , and the initial η , η_0 =20. (E) Corresponding cumulative antibody output. *Insets in* (*C-E*): Corresponding values at day 80.

To examine the effect of antigen availability, we next performed simulations at different 174 values of η . Increasing η resulted in a lower value of the plateau of the average affinity (Fig. 175 2B), indicative of weaker selection. Increasing η would correspond to higher vaccine dosages. 176 B cells with lower affinities were selected with higher η because more opportunities were 177 available for antigen acquisition. Thus, the average affinity plateaued at ~ 3.4 when n=15 and 178 decreased further with larger η (Fig. 2B inset). This is consistent with the classic observations 179 of poorer affinity maturation with increasing antigen levels (26, 39). In terms of the absolute 180 antibody titres, our simulations predicted that unless the selection stringency was so large that 181 the GC B cell population began to decline causing GC collapse (Fig. S1), the GC B cell 182 population was maintained, leading to a steady output of Abs from the GC (Fig. S2). The lower 183 affinity with increasing n thus resulted in a corresponding decrease in the affinity-weighted 184 cumulative antibody output in our simulations (Fig. 2C). The latter output was \sim 417 when η =7 185 and \sim 216 when η =15 at 80 d following dosing (Fig. 2C inset). This affinity-weighted antibody 186 output would serve as a measure of the humoral response elicited by vaccination; it accounts 187 for the effects of both the quality and the quantity of the response. At very high values of η , 188 beyond ~20 in our simulations, the effect of varying η was minimal (Fig. 2B and C), indicating 189 that at sufficiently high dosages, the effect of varying dosage on the GC reaction may not be 190 significant. At lower η , between 7 and 15 in our simulations, lowering dosage resulted in a 191 substantial gain in the GC response. When η was too low, however, in our simulations, GCs 192 collapsed, as not enough antigen was available for sustaining the B cell population (Fig. S1). 193

Following vaccination, antigen levels are expected to decline exponentially with time. We therefore next performed simulations with η decreasing with a half-life τ ; i.e., $\eta = \eta_0 \exp(-t \times \ln 2/\tau)$, where η_0 is the peak antigen level achieved soon after dosing. How antigen levels quantitatively decay on follicular dendritic cells within GCs relative to that in plasma is not well understood (34, 51, 52). We therefore examined a range of values of τ . We found in our simulations with η_0 =20, that the average affinity was higher when τ was lower (Fig. 2D). Specifically, the average affinity at day 80 from the start of the GC reaction was ~6.7 for τ =40 d and ~3.4 for τ =160 d (Fig. 2D inset). The faster decay of antigen thus increased the selection stringency within the GC and led to higher affinity B cells. The affinity-weighted cumulative antibody output, accordingly, increased with decreasing τ , consistent with an improved response due to increased selection stringency (Fig. 2E).

Prime-boost vaccination: the effect of dosage

We now applied our simulations to mimic the prime-boost vaccination protocols employed in clinical trials (5). Specifically, we considered low dose (which we set using $\eta_0=10$) and standard dose (η_0 =20) combinations, administered with a dosing interval Δ =28 d mimicking experimental protocols (5, 6, 21). (Our conclusions are not sensitive to these parameter settings; see Fig. S3) An important aspect of the humoral response associated with multiple antigen dosing that remains unknown is whether the subsequent doses modulate GCs formed following the first dose or seed new GCs. GCs have been observed to persist over extended durations following COVID-19 vaccination (24). (Such persistent GCs have been

seen following natural infection with other viruses too (25).) If the interval Δ is relatively small, 215 one may expect the boost to modulate ongoing GC reactions, as has been suggested previously 216 (34, 39). However, if Δ is large, then the GCs formed by the prime may collapse due to antigen 217 decay before the boost, so that the seeding of new GCs by the boost is more likely. In the latter 218 scenario, the effect of the prime must come from the preferential seeding by memory B cells 219 formed following the prime (47, 48, 53). Recruitment of memory B cells into GCs has been 220 suggested, especially those B cells that displayed cross reactivity to other circulating human 221 betacoronaviruses (24). We therefore simulated two limiting scenarios (Fig. 1B): First, we 222 assumed that the boost modulated existing GCs and seeded no new GCs. Second, we let the 223 boost seed GCs using the memory B cells formed from the prime and not modulate any existing 224 GCs. We also simulated a control case where the boost established new GCs de novo, without 225 using memory B cells from the prime, in which case no advantage from the prime is expected. 226 With the boost modulating existing GCs, our simulations predicted an advantage of the 227 low dose prime over the standard dose prime (blue and red lines in Fig. 3A, B). The average 228 affinity increased with time more steeply with the low dose until day 28, when the boost was 229 administered (Fig. 3A). Just prior to boost administration, the average affinity was ~4.9 for the 230 low dose versus ~2.8 for the standard dose prime. Correspondingly, the affinity-weighted 231 cumulative antibody output was higher for the low dose than the standard dose (Fig. 3B). The 232 administration of the boost caused an increase in antigen availability (Fig. 3A inset), relieving 233 the selection stringency. The average affinity thus saw a temporary dip (Fig. 3A). However, as 234 affinity maturation continued, the higher affinity B cells selected with the low dose prime 235 expanded substantially, yielding a much higher affinity-weighted antibody output than with the 236

standard dose prime (Fig. 3B). The average affinity and the affinity-weighted cumulative antibody output was higher with the low dose prime than the standard dose prime throughout our simulations.




Figure 3. Influence of different prime-boost dosages. (A) Time-evolution of the average affinity of GC B cells for different dosing protocols indicated. *Inset*: The associated antigen levels. (B) Time-evolution of the affinity-weighted cumulative antibody output for the cases in (A). *Inset*: Corresponding values at the final simulation time point. Parameters used: Δ =28 d; τ =40 d; η_0 =10 for LD and η_0 =20 for SD.

When we let the boost seed GCs using memory B cells from the prime, the difference between low dose and standard dose prime was smaller in our simulations following the boost (green and orange curves in Fig. 3A, B). This is because we assumed that only B cells above a certain affinity for the antigen (here, match length \geq 3; see Methods) could differentiate into memory B cells following stimulation. The advantage of the low dose prime in yielding high affinity B cells was thus reduced. The choice of memory B cells is in keeping with the expectation that low affinity naïve-like B cells may not receive strong enough signals to differentiate into switched memory B cells (54). Also, low affinity B cells are likely to exist

regardless and thus seeding GCs with low affinity memory B cells may be no different from seeding GCs *de novo*. Yet, even within the memory pool, the low dose prime yielded higher affinity B cells than the standard dose prime, explaining the advantage of the low dose prime in our simulations (Fig. 3A). The differences in the corresponding affinity-weighted cumulative antibody output (Fig. 3B) were as expected but commensurately smaller than when the boost seeded existing GCs. Both scenarios yielded better responses than the control case where the boost seeded GCs *de novo* (grey lines in Fig. 3A, B).

Prime-boost vaccination: the effect of dosing interval

257

258

259

260

261

262

263

264

265

To assess the influence of the dosing interval, we compared next the antibody responses 266 elicited by two dosing intervals, Δ =28 d and Δ =56 d. We let τ =80 d here to avoid GC collapse 267 following low dose prime with shorter antigen half-lives (Fig. S4). The average GC B cell 268 affinity was significantly higher with $\Delta=56$ d than $\Delta=28$ d when the GCs were allowed to persist 269 until the boost (Fig. 4A, B). For instance, the average affinity was ~6.6 and ~4.4, respectively, 270 in the two cases, just before the administration of the boost following low dose prime, because 271 affinity maturation continued longer with the longer dosing interval. Besides, the declining 272 antigen levels further increased selection stringency in the latter case. This qualitative trend 273 remained with the standard dose prime. The affinity-weighted cumulative antibody output was 274 also significantly higher with the Δ =56 d than Δ =28 d (Fig. 4C, D). For instance, 28 d after the 275 boost, the output was ~380 and ~174, respectively, in the two cases, when low dose prime was 276 used and the boost modulated existing GCs. With standard dose prime too, the difference was 277 nearly 2-fold. This effect remained whether the boost seeded new GCs or modulated surviving 278

GCs (Fig. 4A-D), indicating a distinct advantage of the longer interval. The cases all yielded significantly better responses than the control case where the boost elicited GCs *de novo* (Fig. 4A-D).

Because the selection stringency depended on antigen half-life, τ , we assessed the effect 282 of varying Δ for a range of values of τ . Following recent experiments (9, 12), we also 283 considered much larger values of Δ ; ranging from 28 d to 84 d (Figs. 4E, F and S4). To evaluate 284 the effect on affinity maturation, we compared the maximum value of the average GC B cell 285 affinity achieved at any time 1 week post the boost (to eliminate transients). We found that at 286 any τ , increasing Δ increased the peak affinity, regardless of the use of low dose or standard 287 dose prime or whether the boost seeded new GCs or affected existing GCs (Fig. 4E). Thus, a 288 longer duration yielded a GC response of better quality. Further, the lower was τ , the higher 289 was the peak affinity at any Δ , consistent with stronger selection stringency associated with 290 lower antigen availability (Fig. 4E). 291 This latter effect influenced the overall response, combining quality with quantity, which we 292 assessed using the affinity-weighted cumulative antibody output 28 d post the boost (Fig. 4F). 293 While the overall trend of improved output with longer Δ remained, the trend was more 294 nuanced. The nuances were due to the complex dynamics of the GC responses following 295 multiple dosing. We examined first the effect of low dose prime. When τ was large, the GC 296 reaction was sustained longer, allowing greater affinity maturation (Fig. S4). Thus, delayed 297 dosing interval would lead to better responses. Indeed, with Δ =56 d and Δ =84 d, our simulations 298 predicted that the cumulative output improved with τ (Fig. 4F). With Δ =28 d, the GCs may not 299




Figure 4. Influence of prime-boost dosing interval. (A, B) Average GC B cell affinities, and 301 (C, D) affinity-weighted Ab outputs, with prime-boost intervals (Δ) of either 28 d (A, C) or 56 302 d (B, D), and with LD/SD or SD/SD dosing. Bottom inset of (A): LD and SD correspond to 303 η_0 =10 and 20, respectively, with τ =80 d. Top insets in (A-D): values at the final time point. 304 Heatmaps of (E) the maximum GC affinity recorded between 1 week post boost administration 305 and the final time point, and (F) the affinity-weighted cumulative Ab output 28 d post the boost, 306 as a function of τ (20, 40 and 80 d) and Δ (4, 8, and 12 weeks) for the two limiting scenarios 307 (Mem. reseed and Cont. GC). Trajectories corresponding to the heatmaps are shown in Figure 308 S4. Black regions in (E) correspond to collapsed GCs. A heatmap of the affinity-weighted 309 cumulative Ab output 56 d post the boost is shown in Figure S4C. 310

have expanded sufficiently before the boost. With low τ , leading to high selection stringency, GCs tended to collapse after the boost (Fig. S4). With large τ , the selection stringency was weaker and it therefore took longer for affinities to rise. Consequently, intermediate τ yielded the best response (Fig. 4F).

311

With standard dose prime, too, the effects were similar. The GCs were sustained longer 316 317 as τ increased, but weaker selection due to greater antigen availability led to poorer affinity maturation (Fig. S4). The trade-off tended to yield the best response at intermediate τ . In our 318 simulations, when the boost contributed to existing GCs, it was not efficient in rescuing GCs 319 that were beginning to collapse. Thus, with low and intermediate τ , GCs tended to collapse 320 (Fig. S4). When the boost was assumed to seed new GCs using memory cells from the prime, 321 because the latter had higher affinities for the antigen, the GCs not only survived, but also 322 expanded. The benefit was amplified with delayed dosing as better memory cells became 323 available for seeding the GCs. Thus, as long as τ was not too small, the cumulative output 324 tended to improve with increasing Δ (see τ =40 d and 80 d in Fig. 4F). (With very small τ , the 325 increased GC collapse compromised the response at high Δ ; see τ =20 d in Fig. 4F). These 326

trends were maintained when the output was considered 56 d post boost (Fig. S4). That GCs following COVID-19 vaccination can persist over extended durations (24) suggests that GC shrinkage may be slow *in vivo*. Large dosing intervals would then improve responses, as has been observed in clinical trials (9).

DISCUSSION

331

332

Understanding the reasons behind the improved efficacy of COVID-19 vaccines upon 333 delaying the boost dose or using a low dose prime would aid optimal deployment of vaccines, 334 critical to settings with limited supplies. Here, using comprehensive stochastic simulations of 335 the GC reaction post vaccination, we elucidated plausible mechanistic origins of the improved 336 efficacy. To our knowledge, ours is the first study to employ such simulations to assess the 337 influence of COVID-19 vaccination protocols. The GC reaction is constrained by a quality-338 quantity trade-off (26, 34, 35, 39): Lower antigen availability in the GC leads to more stringent 339 B cell selection, resulting in the production of higher affinity antibodies but in smaller amounts. 340 Increasing antigen availability reverses these effects. The different dosing protocols used—low 341 versus standard dose prime and different dosing intervals—affect this trade-off. With low dose 342 prime, antigen availability in the GCs is lowered, resulting in the selection of high affinity GC 343 B cells. The boost relaxes the selection stringency and allows the expansion of the selected B 344 cells. Delaying the boost delays the relaxation, resulting in even higher affinity B cells getting 345 selected following the prime. Following the boost, these latter B cells would result in better 346 overall GC responses, explaining the observed improvements in efficacy. 347

Experimental evidence supports the above reasons. Antibody titres targeting the SARS-CoV-2 spike were measured in individuals administered the boost 8-12 weeks, 15-25 weeks, and 44-45 weeks after the prime (9). The titres were consistently higher in the individuals with the longer dosing intervals. However, interestingly, the titres just before the boost, were lower in the individuals with the longer intervals. This was consistent with lower antibody output due to declining antigen availability with time in the GC and the associated GC shrinkage. Furthermore, the higher corresponding selection stringency may have resulted in the selection of GC B cells and memory B cells with higher affinity, which would be expected to rescue shrinking GCs or seed new GCs better, explaining the better responses eventually observed. Improved antibody responses following delayed boost dosing has now been observed with multiple vaccines (9-12).

With dosing intervals smaller than 8-12 weeks or with the low dose prime, the differences in antibody titres have been less apparent (5, 8, 21). Yet, the improvement in vaccine efficacy is substantial (5). While we have argued that this improvement may be due to the improved affinity of the antibodies, direct measurements of affinity are lacking. *In vitro* pseudo-typed virus neutralization efficiency of antibodies isolated 28 d after the boost were not significantly different between individuals administered the low dose prime or the standard dose prime or when both standard doses were administered with a 28 d or 56 d interval (5, 8, 21). It is possible that the improvements in affinity may not be adequate to be manifested as improved *in vitro* neutralization efficiencies, possibly because the stoichiometry of antibody binding to the viral spike proteins that ensures virus neutralization (55-57), which is yet to be estimated for SARS-CoV-2, may be realized in both scenarios. *In vitro* neutralization

370

371

372

373

374

375

376

377

efficiencies tend to be much higher than corresponding *in vivo* efficiencies (58). Nonetheless, greater affinity maturation with lower antigen availability has been long recognized as a hallmark of the GC reaction (26, 34, 35, 39). In independent studies on HIV vaccination, for instance, protocols that allowed antigen levels to rise with time, akin to low dose prime followed by standard dose boost examined here, elicited better antibody responses than protocols that held the antigen levels constant or allowed them to decline with time (34), an effect consistent with the dosing protocols modulating antigen availability and the associated quality-quantity trade-off in the GCs (39).

Our simulations predicted a role for antigen half-life in the response to vaccination. With 378 longer half-lives, the response improved upon increasing the dosing interval. With shorter half-379 lives, if associated GC shrinkage was too drastic before the administration of the boost, the 380 response following the boost was compromised. Shorter dosing intervals then elicited the best 381 response. We note here that the antigen half-life in the GC may be difficult to estimate (34, 51, 382 52). That GC B cells and plasmablasts were detectable in high frequencies even 12 weeks after 383 the boost suggests that antigen presented by COVID-19 vaccines may be much longer lasting 384 in the GCs than expected from their half-life in circulation (24). Such prolonged GC responses 385 have been observed in other settings (25). Future studies may yield accurate estimates of the 386 antigen half-life in GCs, which would help identify optimal dosing intervals for the different 387 COVID-19 vaccines available. 388

Quantitative comparison of our predictions with experimental observations is difficult, as has been the case with other modeling studies of the GC reaction (34-36, 39, 40, 42, 45). This is because a number of key biological processes associated with the GC reaction remain

to be elucidated, including the link between dosage and the number of GCs seeded, and between 392 measurable antigen levels in circulation and those within individual GCs (22, 23, 34, 35, 39). 393 Only recently have these links begun to be evaluated (37). As a simplification, our simulations 394 have assumed that increased dosage leads to increased antigen availability within GCs while 395 keeping the number of GCs seeded fixed. It is possible that the number of GCs seeded may 396 also increase with dosage but with a commensurately smaller rise in the antigen levels per GC. 397 Future studies that elucidate the links above may help define these quantities better. 398 Nonetheless, the poorer quality of the antibody response with increasing dosage is a widely 399 observed and accepted phenomenon (26, 34, 39), giving us confidence in our findings. 400

We recognize that other arms of the immune system that could be triggered by the vaccines, particularly T cells, may affect the vaccine efficacies realized (5-9, 13, 14). The strength and timing of the T cell response has been argued to be important in determining the severity of the infection (59), which in turn may affect the estimated vaccine efficacy (60). We have focused here on the antibody response, to which the efficacies have been found to be strongly correlated (18, 19, 60), and which in our simulations qualitatively explained the effects of the different dosing protocols on vaccine efficacies.

401

402

403

404

405

406

407

Other hypotheses have been proposed to explain the effects of low dose prime and delayed dosing intervals, the predominant of which has been the undesirable response to the adenoviral vector in the case of the Oxford/AstraZeneca vaccine that could blunt the response to the boost (61). While these hypotheses remain to be tested, that the effects are now evident with more than one vaccine, including lipid nanoparticle mRNA vaccines that do not use the

adenoviral vectors (10-13), suggests that the effects are intrinsic to the responses elicited by the SARS-CoV-2 antigens in the vaccines, supporting our hypothesis.

In summary, our study offers an explanation of the confounding effects of different dosages and dosing protocols on COVID-19 vaccine efficacies. The resulting insights would inform studies aimed at designing optimal vaccine deployment strategies.

We developed the following in silico stochastic simulation model of the GC reaction

METHODS

418

419

420

421

Stochastic simulations of the GC reaction

(Fig. 1A). The model builds on a previous study which examined the role of passive 422 immunization on the GC reaction (39). Here, we adapted it describe the effect of COVID-19 423 vaccination. 424 **Initialization.** We initiated the GC reaction with N=1000 GC B cells of low affinity for the 425 target antigen in the light zone of the GC. This follows observations where low affinity seeder 426 B cells initiate the GC reaction by proliferating rapidly to a steady state size of 1000 cells. 427 following which somatic hypermutation and affinity maturation commence (36, 39). We 428 considered a non-mutating antigen, determined by a randomly chosen string of length L and 429 alphabet of size $\kappa=4$. The alphabet size represents the broad classes of amino acids, namely, 430 positively charged, negatively charged, polar, and hydrophobic (42). The B cell receptor (BCR) 431 paratope for each cell is then set by randomly mutating the antigen sequence at L-1 randomly 432 chosen positions. This ensured that the cells in the initial pool all had low affinities for the 433 antigen. The B cells were then allowed to acquire antigen. 434

435

Antigen acquisition. Antigen is presented to B cells as antibody-bound immune complexes on follicular dendritic cell surfaces. The probability with which a B cell successfully acquired the 436 antigen was $f_{Ag} = (\varepsilon - \omega + L)/2L$, where ε and ω are the lengths of the longest common 437 substrings of the antigen sequence and those of the associated B cell receptor (BCR) and the 438 presenting antibody, respectively. The latter expression followed from a mechanistic 439 consideration of bond dissociation triggered by the competition between the BCR and the 440 antibody for the antigen (39). Note that antibodies are secreted versions of the BCRs and hence 441 were similarly represented as bit-strings of length L too. The presenting antibodies were 442 produced by plasma cells and re-entered the GC via antibody feedback, described below. B 443 cells were selected at random for antigen acquisition, with each B cell selected n times on 444 average. The amount of antigen acquired by a B cell was set equal to the number of successful 445 acquisition attempts, denoted as θ . B cells had to acquire a minimum amount of antigen, 446 denoted θ_c , for them to survive. Surviving cells were eligible to receive help from T follicular 447 helper (T_{fh}) cells. We capped the level of antigen acquired at θ_{∞} , at which point the B cell may 448 have received saturating levels of stimulatory signals necessary for T_{fh} cell help. 449 T_{fh} cell help. We chose surviving B cells randomly and let each cell receive T_{fh} cell help with 450 the probability $f_T = (\theta - \theta_{\min})/(\theta_{\max} - \theta_{\min})$, where θ_{\min} is the minimum antigen acquired by the 451 surviving B cells and θ_{max} (=min (η, θ_{∞})) is the maximum antigen acquired. The probability 452 follows from the recognition that T_{fh} cell help depends on the relative and not absolute amount 453 of antigen acquired (23, 39). Cells that do not receive help died. We continued this with every 454 surviving cell and stopped if 250 cells successfully received $T_{\rm fh}$ help. 455

Cell fate decision. Of the cells selected above, we chose 5% randomly to become memory B 456 cells; 5% to become plasma cells; and the rest to migrate to the dark zone of the GC. The 457 memory B cells were constrained to have a minimum affinity for the antigen (54) (here, match 458 length 3) and were allowed to survive long-term. The plasma cells exited the GC, commenced 459 producing antibodies, and died at the rate of 0.015 per generation (Table S1). 460 **Proliferation and mutation.** The cells in the dark zone were allowed to multiply, with each 461 cell dividing twice. Of the resulting cells, we chose 10% and introduced single random point 462 mutations in their BCR sequences. The latter frequency was chosen following estimates based 463 on the somatic hypermutation frequency suggesting that 1 in 10 GC B cells would be mutated 464 per generation in their antibody variable region genes (23, 36, 39, 42). The two divisions per 465 cell would bring the cell population back to the N~1000 cells. This completed one generation 466 of B cell evolution in the GC. 467 **Recycling.** The resulting cells in the dark zone were all allowed to migrate to the light zone, 468 offering the next generation of cells on which the above process would repeat. 469 Antibody feedback. Antibodies produced by plasma cells could traffic back to the GC and 470 influence antigen presentation (35). Accordingly, following estimated trafficking timescales, 471 we let antibodies produced by plasma cells in any generation become the antibodies presenting 472 antigen to B cells two generations later (35, 39). Antibodies were also systemically cleared at 473 the rate of 0.01165 per generation (Table S1). 474 **Termination.** We repeated the above process for up to 250 generations (~18 weeks) or if the 475 cell population declined, leading to GC collapse. 476

Dosing protocol

478

We implemented the prime-boost dosing protocol by letting η vary with time as 479 $\eta = \eta_0 \exp(-t \times \ln 2/\tau)$, mimicking antigen rise immediately upon dosing (to η_0) and an exponential 480 decline subsequently with half-life τ (34, 39, 46). The decline is assumed to subsume any loss 481 of antigen due to acquisition by B cells. We set η_0 based on whether a low or standard dose 482 was employed. The prime and boost were separated by the duration Δ . Our interest is in large 483 values of Δ and low first dosages, so that at the time of boost administration, the residual antigen 484 is small. Whether memory B cells seed GCs post boost is a topic of active current research (47, 485 48, 53, 54, 62, 63). We therefore considered all potential scenarios, with the boost 1) feeding 486 into existing GCs; 2) seeding new GCs using memory B cells; 3) seeding new GCs using naïve 487 B cells. In scenario 2, we let the memory B cells for seeding the GCs be chosen with a 488 probability proportional to their affinity for the antigen. In other words, the distribution of B 489 cells of different affinities in the seeder pool mimics the distribution of affinity-weighted 490 fractions of memory B cells formed following the prime. 491

Parameter values

492

493

494

495

496

497

498

499

The parameter values employed and their sources are listed in Table S1.

Quantification of the GC response

With each parameter setting, we performed 2500 realizations, which we divided into 25 ensembles of 100 GC realizations each (39). The average GC B cell affinity in the g^{th} generation was calculated using,

500
$$\alpha(g) = \left\langle \frac{\sum_{i=1}^{100} \sum_{j=1}^{n_i(g)} a_{ij}(g)}{\sum_{i=1}^{100} n_i(g)} \right\rangle_{25}$$

where a_{ij} was the affinity of the j^{th} B cell among the $n_i(g)$ B cells in the g^{th} generation of the i^{th} realization of an ensemble. The angular brackets represent averaging across the ensembles. The affinity-weighted plasma cell output in the g^{th} generation was

$$w(g) = \left\langle \sum_{i=1}^{100} \sum_{\varepsilon=1}^{L} p_{\varepsilon}^{i}(g) \frac{\varepsilon}{L} \right\rangle_{25}$$

where $p_{\varepsilon}^{i}(g)$ was the number of plasma cells with affinity ε in the g^{th} generation. If plasma cells died at the per capita rate δ_{p} , then the affinity-weighted cumulative plasma cell output would be

508
$$P(g) = \sum_{\varphi=1}^{g} w(\varphi) \exp(-\delta_p(g - \varphi)).$$

If the antibody production rate of plasma cells was β per generation (64), the instantaneous affinity-weighted antibody output would be $\beta P(g)$, which given the clearance rate, δ_A , of circulating antibodies yielded the affinity-weighted cumulative antibody output as

512
$$\gamma(g) = \sum_{\varphi=1}^{g} \beta P(\varphi) \exp(-\delta_A(g - \varphi)).$$

We performed the simulations and analysed the results using programs written in MATLAB.

COMPETING INTERESTS

514

515

517

The authors declare that no conflicts of interests exist.

REFERENCES

- 519 1. O. J. Wouters *et al.*, Challenges in ensuring global access to COVID-19 vaccines: production, affordability, allocation, and deployment. *Lancet* **397**, 1023-1034 (2021).
- 521 2. G. Forni, A. Mantovani, COVID-19 vaccines: where we stand and challenges ahead. *Cell Death Differ* **28**, 626-639 (2021).
- 523 3. C. M. Saad-Roy *et al.*, Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes. *Science* 10.1126/science.abg8663 (2021).
- 525 4. K. M. Bubar *et al.*, Model-informed COVID-19 vaccine prioritization strategies by age and serostatus. *Science* **371**, 916-921 (2021).
- 527 5. M. Voysey *et al.*, Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. *Lancet* **397**, 881-891 (2021).
- M. Voysey *et al.*, Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.
 Lancet 397, 99-111 (2021).
- 7. P. M. Folegatti *et al.*, Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial. *Lancet* **396**, 467-478 (2020).
- 536 8. M. N. Ramasamy *et al.*, Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. *Lancet* **396**, 1979-1993 (2021).
- A. Flaxman *et al.*, Tolerability and immunogenicity after a late second dose or a third dose of ChAdOx1 nCoV-19 (AZD1222). *Preprint* 10.2139/ssrn.3873839., https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3873839 (2021).
- 542 10. H. Parry *et al.*, Extended interval BNT162b2 vaccination enhances peak antibody generation in older people. *medRxiv* 10.1101/2021.05.15.21257017, 2021.2005.2015.21257017 (2021).
- H. Victoria *et al.*, Delayed interval BNT162b2 mRNA COVID-19 vaccination provides robust immunity. *Nature Portfolio* 10.21203/rs.3.rs-793234/v1 (2021).
- R. Payne *et al.* (2021) Sustained T cell immunity, protection and boosting using extended dosing intervals of BNT162b2 mRNA vaccine. https://www.pitch-study.org/PITCH_Dosing_Interval_23072021.pdf
- J. Mateus *et al.*, Low dose mRNA-1273 COVID-19 vaccine generates durable T cell memory and antibodies enhanced by pre-existing crossreactive T cell memory. *medRxiv* 10.1101/2021.06.30.21259787, 2021.2006.2030.21259787 (2021).
- 552 14. M. Sadarangani, A. Marchant, T. R. Kollmann, Immunological mechanisms of vaccine-induced protection against COVID-19 in humans. *Nat Rev Immunol* **21**, 475-484 (2021).
- L. R. Baden *et al.*, Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. *N Engl J Med* 384, 403-416 (2021).
- D. Y. Logunov *et al.*, Safety and efficacy of an rAd26 and rAd5 vector-based heterologous primeboost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia. *Lancet* **397**, 671-681 (2021).
- 559 17. F. P. Polack *et al.*, Safety and efficacy of the BNT162b2 mRNA COVID-19 Vaccine. *N Engl J Med* 383, 2603-2615 (2020).
- 561 18. D. S. Khoury *et al.*, Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. *Nat Med* 10.1038/s41591-021-01377-8 (2021).
- 563 19. K. A. Earle *et al.*, Evidence for antibody as a protective correlate for COVID-19 vaccines. *Vaccine* 39, 4423-4428 (2021).
- F. Krammer, A correlate of protection for SARS-CoV-2 vaccines is urgently needed. *Nat Med* **27**, 1147-1148 (2021).

- J. R. Barrett *et al.*, Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses. *Nat Med* **27**, 279-288 (2021).
- J. G. Cyster, C. D. C. Allen, B cell responses: cell interaction dynamics and decisions. *Cell* **177**, 524-570 540 (2019).
- 571 23. G. D. Victora, M. C. Nussenzweig, Germinal centers. Annu Rev Immunol 30, 429-457 (2012).
- J. S. Turner *et al.*, SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses.

 Nature 10.1038/s41586-021-03738-2 (2021).
- 574 25. C. W. Davis *et al.*, Longitudinal analysis of the human B cell response to Ebola virus infection. *Cell* **177**, 1566-1582.e1517 (2019).
- 576 26. H. N. Eisen, G. W. Siskind, Variations in affinities of antibodies during the immune response. 577 *Biochemistry* **3**, 996-1008 (1964).
- 578 27. M. Bonsignori *et al.*, Maturation pathway from germline to broad HIV-1 neutralizer of a CD4-mimic antibody. *Cell* **165**, 449-463 (2016).
- 580 28. J. Foote, H. N. Eisen, Kinetic and affinity limits on antibodies produced during immune responses.

 581 *Proc Natl Acad Sci U S A* **92**, 1254-1256 (1995).
- J. Foote, H. N. Eisen, Breaking the affinity ceiling for antibodies and T cell receptors. *Proc Natl Acad Sci U S A* **97**, 10679-10681 (2000).
- R. Desikan, R. Antia, N. M. Dixit, Physical 'strength' of the multi-protein chain connecting immune cells: Does the weakest link limit antibody affinity maturation? *Bioessays* **43**, e2000159 (2021).
- J. M. Tas *et al.*, Visualizing antibody affinity maturation in germinal centers. *Science* **351**, 1048-1054 (2016).
- 588 32. E. Natkanski *et al.*, B cells use mechanical energy to discriminate antigen affinities. *Science* **340**, 1587-1590 (2013).
- 590 33. K. Kwak *et al.*, Intrinsic properties of human germinal center B cells set antigen affinity thresholds. *Sci Immunol* **3** (2018).
- H. H. Tam *et al.*, Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination. *Proc Natl Acad Sci U S A* **113**, E6639-E6648 (2016).
- 594 35. Y. Zhang *et al.*, Germinal center B cells govern their own fate via antibody feedback. *J Exp Med* **210**, 457-464 (2013).
- 596 36. S. Wang *et al.*, Manipulating the selection forces during affinity maturation to generate cross-reactive HIV antibodies. *Cell* **160**, 785-797 (2015).
- 598 37. Y. Kato *et al.*, Multifaceted effects of antigen valency on B cell response composition and differentiation in vivo. *Immunity* **53**, 548-563 e548 (2020).
- T. Schoofs *et al.*, HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. *Science* **352**, 997-1001 (2016).
- A. K. Garg, R. Desikan, N. M. Dixit, Preferential presentation of high-affinity immune complexes in germinal centers can explain how passive immunization improves the humoral response. *Cell Rep* **29**, 3946-3957 e3945 (2019).
- R. J. De Boer, A. S. Perelson, How germinal centers evolve broadly neutralizing antibodies: The breadth of the follicular helper T cell response. *J Virol* **91** (2017).
- M. Meyer-Hermann *et al.*, A theory of germinal center B cell selection, division, and exit. *Cell Rep* **2**, 162-174 (2012).
- S. Luo, A. S. Perelson, Competitive exclusion by autologous antibodies can prevent broad HIV-1 antibodies from arising. *Proc Natl Acad Sci U S A* **112**, 11654-11659 (2015).
- M. Oprea, A. S. Perelson, Somatic mutation leads to efficient affinity maturation when centrocytes recycle back to centroblasts. *J Immunol* **158**, 5155-5162 (1997).
- T. B. Kepler, A. S. Perelson, Cyclic re-entry of germinal center B cells and the efficiency of affinity maturation. *Immunol Today* **14**, 412-415 (1993).
- 615 45. V. I. Zarnitsyna, J. Lavine, A. Ellebedy, R. Ahmed, R. Antia, Multi-epitope models explain how pre-
- existing antibodies affect the generation of broadly protective responses to influenza. *PLoS Pathog* **12**, e1005692 (2016).

- K. A. Pape, D. M. Catron, A. A. Itano, M. K. Jenkins, The humoral immune response is initiated in lymph nodes by B cells that acquire soluble antigen directly in the follicles. *Immunity* **26**, 491-502 (2007).
- 621 47. K. A. Pape, M. K. Jenkins, Do memory B cells form secondary germinal centers?: it depends. *Cold Spring Harb Perspect Biol* **10**, a029116 (2018).
- 623 48. M. J. Shlomchik, Do memory B cells form secondary germinal centers?: yes and no. *Cold Spring Harb Perspect Biol* **10**, a029405 (2018).
- K. Tripathi, R. Balagam, N. K. Vishnoi, N. M. Dixit, Stochastic simulations suggest that HIV-1 survives close to its error threshold. *PLoS Comput Biol* **8**, e1002684 (2012).
- S. Gadhamsetty, N. M. Dixit, Estimating frequencies of minority nevirapine-resistant strains in chronically HIV-1-infected individuals naive to nevirapine by using stochastic simulations and a mathematical model. *J Virol* **84**, 10230-10240 (2010).
- B. A. Heesters, C. E. van der Poel, A. Das, M. C. Carroll, Antigen presentation to B cells. *Trends Immunol* 37, 844-854 (2016).
- B. A. Heesters, R. C. Myers, M. C. Carroll, Follicular dendritic cells: dynamic antigen libraries. *Nat Rev Immunol* 14, 495-504 (2014).
- L. J. McHeyzer-Williams, C. Dufaud, M. G. McHeyzer-Williams, Do memory B cells form
 secondary germinal centers?: impact of antibody class and quality of memory T-cell help at recall.
 Cold Spring Harb Perspect Biol 10, a028878 (2018).
- F. Weisel, M. Shlomchik, Memory B cells of mice and humans. *Ann Rev Immunol* **35**, 255-284 (2017).
- 639 55. O. F. Brandenberg *et al.*, Predicting HIV-1 transmission and antibody neutralization efficacy in vivo from stoichiometric parameters. *PLoS Pathog* **13**, e1006313 (2017).
- 56. S. N. Mulampaka, N. M. Dixit, Estimating the threshold surface density of Gp120-CCR5 complexes necessary for HIV-1 envelope-mediated cell-cell fusion. *PLoS One* **6**, e19941 (2011).
- P. Padmanabhan, N. M. Dixit, Mathematical model of viral kinetics in vitro estimates the number of E2-CD81 complexes necessary for hepatitis C virus entry. *PLoS Comput Biol* **7**, e1002307 (2011).
- 645 58. M. J. van Gils, R. W. Sanders, In vivo protection by broadly neutralizing HIV antibodies. *Trends Microbiol* **22**, 550-551 (2014).
- B. Chatterjee, H. S. Sandhu, N. M. Dixit, The relative strength and timing of innate immune and CD8
 T-cell responses underlie the heterogeneous outcomes of SARS-CoV-2 infection. *medRxiv* 10.1101/2021.06.15.21258935, 2021.2006.2015.21258935 (2021).
- 650 60. P. Padmanabhan, R. Desikan, N. M. Dixit, Modelling the population-level protection conferred by COVID-19 vaccination. *medRxiv* 10.1101/2021.03.16.21253742, 2021.2003.2016.21253742 (2021).
- E. Callaway, Why Oxford's positive COVID vaccine results are puzzling scientists. *Nature* **588**, 16-18 (2020).
- 654 62. L. Mesin *et al.*, Restricted clonality and limited germinal center reentry characterize memory B cell reactivation by boosting. *Cell* **180**, 92-106.e111 (2020).
- 656 63. C. Viant *et al.*, Antibody affinity shapes the choice between memory and germinal center B cell fates. *Cell* **183**, 1298-1311.e1211 (2020).
- 658 64. K. Roberts, B. Alberts, A. Johnson, P. Walter, T. Hunt, Molecular biology of the cell. 4th edition. *New York: Garland Science* (2002).

Supplementary Materials for 661 662 Low dose prime and delayed boost can improve COVID-19 vaccine efficacies by 663 increasing B cell selection stringency in germinal centres 664 665 Amar K. Garg^{1,#}, Soumya Mittal¹, Pranesh Padmanabhan², Rajat Desikan^{1,‡}, Narendra M. Dixit^{1,3,*} 666 667 ¹Department of Chemical Engineering, Indian Institute of Science, Bangalore, India 560012 668 ²Clem Jones Centre for Ageing Dementia Research, Queensland Brain Institute, The University of Queensland, 669 Brisbane, Australia 4072 670 ³Centre for Biosystems Science and Engineering, Indian Institute of Science, Bangalore, India 560012 671 #Current Address: Helmholtz Centre for Infection Research, Braunschweig, Germany 672 [‡]Current Address: Certara QSP, Certara UK Limited, Sheffield, UK 673 674 *Correspondence: 675 Narendra M. Dixit 676

Email: narendra@iisc.ac.in

677




Figure S1. Influence of \eta. Time series of (A) GC B cell population and (B) percent surviving GCs for simulations with various η . GCs with low η (=5 here) have high rates of apoptosis which result in GCs gradually being extinguished with time. However, these GCs also exhibit accelerated affinity maturation (C) due to the higher selection stringencies. Insets: values at the final time point.




Figure S2. Absolute Ab output. Unweighted cumulative antibody output at the final time point for various (A) η , and (B) τ . Insets: time series. The curves for the different cases overlap.




Figure S3. Influence of initial Ag levels (dose) and the prime-boost dosing interval (Δ). (A) Average GC B cell affinity, and (B) affinity-weighted Ab output with a prime-boost interval Δ =28 d and antigen half-life τ =40 d, either with LD/SD or SD/SD dosing (LD and SD correspond to η_0 =15 and 30, respectively). These trends are qualitatively similar to those in Figure 3. (C) Average GC B cell affinity, and (D) affinity-weighted Ab output with Δ =56 d and τ =40 d, either with LD/SD or SD/SD dosing (LD and SD correspond to the default η_0 =10 and 20, respectively). Insets: values at the final time point.




Figure S4. Influence of the prime-boost dosing interval (Δ). Time series of (A) average GC B cell affinities, and (B) affinity-weighted Ab outputs corresponding to the heatmaps in Figure 4E and 4F, respectively. (C) Heatmaps of the affinity-weighted cumulative Ab output 56 d post the boost, as a function of τ (20, 40 and 80 d) and Δ (4, 8, and 12 weeks) for the two limiting scenarios (Mem. reseed and Cont. GC).

Table S1. Model parameters and their values.

717

718

Symbol	Description	Value (units)	Refs.
N	Number of B cells initiating the GC reaction	1000 (cells)	(36, 39)
L	String length of antigen, B cell receptor (BCR), and antibody	8 (dimensionless)	(39, 42)
К	Alphabet size for strings	4 (dimensionless)	(39, 42)
$ heta_c$	Minimum amount of acquired antigen for B cell survival	3 (dimensionless)	(39)
$ heta_{\infty}$	Maximum amount of antigen that can be acquired by a B cell	5 (dimensionless)	-
δ_p	Clearance rate of plasma cells	0.015 (generation ⁻¹)	(34, 44)
β	Antibody production rate of plasma cells per generation	2000 (molecules cell ⁻¹ s ⁻¹)	(64)
δ_a	Clearance rate of antibodies	0.01165 (generation ⁻¹)	(34, 44)